Murray A Raskind, Elaine R Peskind, Bruce Chow, Crystal Harris, Anne Davis-Karim, Hollie A Holmes, Kimberly L Hart, Miles McFall, Thomas A Mellman, Christopher Reist, Jennifer Romesser, Robert Rosenheck, Mei-Chiung Shih, Murray B Stein, Robert Swift, Theresa Gleason, Ying Lu, Grant D Huang
BACKGROUND: In randomized trials, prazosin, an α1 -adrenoreceptor antagonist, has been effective in alleviating nightmares associated with post-traumatic stress disorder (PTSD) in military veterans. METHODS: We recruited veterans from 13 Department of Veterans Affairs medical centers who had chronic PTSD and reported frequent nightmares. Participants were randomly assigned to receive prazosin or placebo for 26 weeks; the drug or placebo was administered in escalating divided doses over the course of 5 weeks to a daily maximum of 20 mg in men and 12 mg in women...
February 8, 2018: New England Journal of Medicine